HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors Nov 18, 2022 By sarahjibrin
Jul 3, 2020 By sarahjibrin HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy
Jun 22, 2020 By sarahjibrin HiFiBiO Therapeutics Presents Three Novel Immuno-Oncology Programs at 2020 AACR Virtual Annual Meeting II
Mar 30, 2020 By sarahjibrin Droplet Microfluidic Screening and Sequencing Can Vastly Expand the Universe of New Antibody Therapeutics
Mar 30, 2020 By sarahjibrin High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics
Jun 3, 2019 By sarahjibrin HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer
Oct 12, 2017 By Rick Bowen HiFiBiO and collaborators publish single-cell microfluidics work in Nature Biotechnology
Oct 9, 2017 By Rick Bowen Shared Insights About Guiding Principles of Open Collaboration in Drug Discovery Today From HiFiBiO CEO Liang Schweizer
Sep 11, 2017 By Rick Bowen Single-Cell Deep Phenotyping of lgG-Secreting Cells for High-Resolution Immune Monitoring
